No sign Oxford-AstraZeneca vaccine causes blood clots: Canadian health authorities - CTV News | Canada News Media
Connect with us

Business

No sign Oxford-AstraZeneca vaccine causes blood clots: Canadian health authorities – CTV News

Published

 on


OTTAWA —
Canadian health authorities are keeping a watchful eye on European investigations of the Oxford-AstraZeneca vaccine after reports of blood clots following inoculations, but say there is no evidence they were caused by the vaccine.

At least nine European countries hit pause on their use of AstraZeneca’s doses — some entirely, and others only on specific batches — pending further investigation of blood clots, though none suggested there is a link between the clots and getting the vaccine.

Canada’s first 500,000 doses of AstraZeneca are being put to use just this week, and officials in several provinces said Thursday they don’t intend to stop the rollout. 

“At this time, we have no information to suggest that this vaccine poses more risks than any other,” said Dr. Horacio Arruda, director of public health in Quebec.

Carlo Mastrangelo, the head of corporate affairs, communications and sustainability at AstraZeneca Canada, said the company has completed a new safety review of 10 million patients who received the vaccine. He said it uncovered “no evidence of an increased risk of pulmonary embolism or deep vein thrombosis in any defined age group, gender, batch or in any particular country” with its COVID-19 vaccine.

“In fact, the observed number of these types of events are significantly lower in those vaccinated than what would be expected among the general population,” said Mastrangelo.

Dr. Zain Chagla, an infectious disease doctor at St. Joseph’s Hospital in Hamilton, said he has been inundated with calls from family doctors who are supposed to start inoculating patients this weekend, wondering if there was reason to be concerned.

Chagla said he will give the vaccine to patients this weekend as planned, because he trusts that Health Canada, which is constantly monitoring safety reports, would step in if there was any concern.

“Health Canada, they are working 24-7,” he said. “Their role is if there’s anything that goes on, you know that they essentially put a halt to it.”

Health authorities in Denmark, which halted AstraZeneca vaccinations Thursday after an undisclosed number of blood clots were reported, and one patient died, said they stopped using the vaccine to be extra cautious, not because there was an expected connection.

The European Medicines Agency is probing the issue itself but says 30 blood clots in more than five million patients who received the vaccine is not out of step with the normal rate of blood clots in the general population.

Chagla said the normal incidence of blood clots is about one in 1,000 patients over the course of a year. When vaccinating millions of people, it is not unusual to see some of them develop blood clots.

The question is whether they could have had the clot without the vaccine. Chagla said these kind of investigations are totally normal in the rollout of any new pharmaceutical.

“This is what I think the European Union is going through,” he said. “Now they’re trying to say, ‘Hey, is this an issue with the vaccine or are these people that we’re just going to have blood clots regardless?’ And you know, if it was the same thing as being struck by lightning, we would very easily say, ‘Well, OK, the vaccine has nothing to do with people being struck by lightning.”‘

Chagla said if a link is found, it may also be specific to one batch of the vaccine, which also has to be examined. Canada’s doses, he noted, are currently coming from the Serum Institute of India, while Europe is getting its doses from facilities there.

Alberta’s chief medical officer of health, Dr. Deena Hinshaw, said on Twitter that the blood clots are “extremely rare events in an area that is using a lot of this vaccine.”

“There is currently no indication that vaccination has caused these events and the actions these countries have taken is out of an abundance of caution,” she said. “We will continue watching closely and monitoring every dose of the vaccine in Alberta.”

Ontario Health Minister Christine Elliott said the province won’t discontinue AstraZeneca but is working with Health Canada to follow the evidence.

“We are continuing with our AstraZeneca inoculations and we know that several million doses have already been administered around the world with no adverse effects,” she said.

This latest setback for AstraZeneca’s vaccine came just after concerns about its efficacy in seniors started to wane. Several European nations reversed earlier decisions not to give it to people over 65 because there weren’t enough seniors in the clinical trials.

Canada’s National Advisory Committee on Immunization recommended seniors be prioritized for the mRNA vaccines from Pfizer-BioNTech and Moderna, which had more evidence of how they work on seniors.

The chair of the committee, Dr. Caroline Quach, told The Canadian Press the board met Wednesday to discuss newer evidence of how the AstraZeneca vaccine worked for seniors in “real-world” use, and expects an updated statement on the vaccine in Canada “in the next few days.”

This report by The Canadian Press was first published March 11, 2021.

With files from Sidhartha Banerjee in Montreal and Shawn Jeffords in Toronto.

Let’s block ads! (Why?)



Source link

Continue Reading

Business

Roots sees room for expansion in activewear, reports $5.2M Q2 loss and sales drop

Published

 on

 

TORONTO – Roots Corp. may have built its brand on all things comfy and cosy, but its CEO says activewear is now “really becoming a core part” of the brand.

The category, which at Roots spans leggings, tracksuits, sports bras and bike shorts, has seen such sustained double-digit growth that Meghan Roach plans to make it a key part of the business’ future.

“It’s an area … you will see us continue to expand upon,” she told analysts on a Friday call.

The Toronto-based retailer’s push into activewear has taken shape over many years and included several turns as the official designer and supplier of Team Canada’s Olympic uniform.

But consumers have had plenty of choice when it comes to workout gear and other apparel suited to their sporting needs. On top of the slew of athletic brands like Nike and Adidas, shoppers have also gravitated toward Lululemon Athletica Inc., Alo and Vuori, ramping up competition in the activewear category.

Roach feels Roots’ toehold in the category stems from the fit, feel and following its merchandise has cultivated.

“Our product really resonates with (shoppers) because you can wear it through multiple different use cases and occasions,” she said.

“We’ve been seeing customers come back again and again for some of these core products in our activewear collection.”

Her remarks came the same day as Roots revealed it lost $5.2 million in its latest quarter compared with a loss of $5.3 million in the same quarter last year.

The company said the second-quarter loss amounted to 13 cents per diluted share for the quarter ended Aug. 3, the same as a year earlier.

In presenting the results, Roach reminded analysts that the first half of the year is usually “seasonally small,” representing just 30 per cent of the company’s annual sales.

Sales for the second quarter totalled $47.7 million, down from $49.4 million in the same quarter last year.

The move lower came as direct-to-consumer sales amounted to $36.4 million, down from $37.1 million a year earlier, as comparable sales edged down 0.2 per cent.

The numbers reflect the fact that Roots continued to grapple with inventory challenges in the company’s Cooper fleece line that first cropped up in its previous quarter.

Roots recently began to use artificial intelligence to assist with daily inventory replenishments and said more tools helping with allocation will go live in the next quarter.

Beyond that time period, the company intends to keep exploring AI and renovate more of its stores.

It will also re-evaluate its design ranks.

Roots announced Friday that chief product officer Karuna Scheinfeld has stepped down.

Rather than fill the role, the company plans to hire senior level design talent with international experience in the outdoor and activewear sectors who will take on tasks previously done by the chief product officer.

This report by The Canadian Press was first published Sept. 13, 2024.

Companies in this story: (TSX:ROOT)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Business

Talks on today over HandyDART strike affecting vulnerable people in Metro Vancouver

Published

 on

 

VANCOUVER – Mediated talks between the union representing HandyDART workers in Metro Vancouver and its employer, Transdev, are set to resume today as a strike that has stopped most services drags into a second week.

No timeline has been set for the length of the negotiations, but Joe McCann, president of the Amalgamated Transit Union Local 1724, says they are willing to stay there as long as it takes, even if talks drag on all night.

About 600 employees of the door-to-door transit service for people unable to navigate the conventional transit system have been on strike since last Tuesday, pausing service for all but essential medical trips.

Hundreds of drivers rallied outside TransLink’s head office earlier this week, calling for the transportation provider to intervene in the dispute with Transdev, which was contracted to oversee HandyDART service.

Transdev said earlier this week that it will provide a reply to the union’s latest proposal on Thursday.

A statement from the company said it “strongly believes” that their employees deserve fair wages, and that a fair contract “must balance the needs of their employees, clients and taxpayers.”

This report by The Canadian Press was first published Sept. 12, 2024.

The Canadian Press. All rights reserved.

Source link

Continue Reading

Business

Transat AT reports $39.9M Q3 loss compared with $57.3M profit a year earlier

Published

 on

 

MONTREAL – Travel company Transat AT Inc. reported a loss in its latest quarter compared with a profit a year earlier as its revenue edged lower.

The parent company of Air Transat says it lost $39.9 million or $1.03 per diluted share in its quarter ended July 31.

The result compared with a profit of $57.3 million or $1.49 per diluted share a year earlier.

Revenue in what was the company’s third quarter totalled $736.2 million, down from $746.3 million in the same quarter last year.

On an adjusted basis, Transat says it lost $1.10 per share in its latest quarter compared with an adjusted profit of $1.10 per share a year earlier.

Transat chief executive Annick Guérard says demand for leisure travel remains healthy, as evidenced by higher traffic, but consumers are increasingly price conscious given the current economic uncertainty.

This report by The Canadian Press was first published Sept. 12, 2024.

Companies in this story: (TSX:TRZ)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Trending

Exit mobile version